Stephen Quake, Ph.D., is the Lee Otterson Professor of Bioengineering and Applied Physics at Stanford University and Co-President of the Chan Zuckerberg Biohub, a new bioscience collaboration funded through a $600 million commitment by the Chan Zuckerberg Initiative. His interests lie at the nexus of physics, biology, and technology, where he has made numerous contributions to the fields of microfluidics, next-generation sequencing, and genomic analysis. He has been elected to the National Academy of Sciences, the National Academy of Engineering, the Institute of Medicine, the American Physical Society and the American Institute for Medical and Biological Engineering and is the recipient of numerous international awards, including the Human Frontiers of Science Nakasone Prize, the Lemelson-MIT Prize for Innovation, and the Raymond and Beverly Sackler International Prize in Biophysics. He has founded or co-founded several companies including Fluidigm, Helicos Biosciences, Verinata Health (acquired by Illumina), Quanticel Pharmaceuticals (acquired by Celgene), Moleculo (acquired by Illumina), Cellular Research (acquired by Becton Dickinson) and ImmuMetrix (acquired by CareDx). He holds a D.Phil. from the University of Oxford and a B.S. in Physics and a M.S. in Mathematics from Stanford University.
Stephen Quake, Ph.D., Founder, Chair of the Scientific Advisory Board
Larry Corey, M.D.
Larry Corey, M.D., serves as President and Director Emeritus of Fred Hutchinson Cancer Research Center and a member of the faculty in the Vaccine and Infectious Disease Division. He is also Professor of Medicine and Laboratory Medicine and the Lawrence Corey Endowed Chair in Medical Virology at the University of Washington. Dr. Corey is an internationally-renowned expert in virology, T cell immunology, and vaccine development. His research focuses on the immunology of herpesviruses, HIV, and infections related to cancer and he is known for his expertise in translational medicine, clinical trial design, and drug development. He is also Principal Investigator of the HIV Vaccine Trials Network, an international collaboration of scientists and institutions dedicated to accelerating the development of HIV vaccine. Dr. Corey’s honors and awards include election to the American Academy of Arts and Sciences and the National Academy of Medicine branch of the National Academy of Sciences. Dr. Corey received his M.D. and B.S. in Zoology from the University of Michigan. He has authored more than 700 scientific publications, 12 books, and more than 150 book chapters and editorials.
Robert S. Langer, Sc.D.
Robert S. Langer, Sc.D., serves as the David H. Koch Institute Professor at the Massachusetts Institute of Technology. His research is at the interface of medicine, materials science, and chemical engineering with a focus on nanotechnology and the development of new nanoparticles to treat cancer and other diseases. Specifically, he designs polymer, lipid, and polymer-lipid hybrid nanocarriers for improved drug delivery, as well as similarly controlled delivery systems for genetically-engineered therapeutic proteins, DNA, and RNA. Dr. Langer has written over 1,350 articles. He holds over 1,100 issued or pending patents worldwide and his patents have been licensed or sublicensed to over 300 pharmaceutical, chemical, biotechnology, and medical device companies. He is the most cited engineer in history. Dr. Langer has received over 220 major awards including the United States National Medal of Science, the United States National Medal of Technology and Innovation, the 2002 Charles Stark Draper Prize, and the Lemelson-MIT prize, and has been elected to the Institute of Medicine, the National Academy of Engineering and the National Academy of Sciences. He received a B.S. from Cornell University and his Sc.D. from the MIT, both in Chemical Engineering.
Edward Mocarski, Jr., Ph.D.
Edward Mocarski, Jr., Ph.D., serves as the Robert W. Woodruff Professor of Microbiology & Immunology in the Emory Vaccine Center of Emory University and is also Professor Emeritus and former Chair of Microbiology & Immunology at Stanford University. While on leave from Emory University, he served as a Distinguished Fellow at MedImmune, a division of AstraZeneca, where he managed an expansion of vaccine pipeline research with particular attention to herpesviruses, including cytomegalovirus (“CMV”), an opportunistic herpesvirus. Dr. Mocarski’s research focuses on all aspects of the biology and pathogenesis of CMV, specifically, on integrating biochemical, molecular, cellular, and intact animal approaches to investigate the biological properties of this virus and its close relatives. He has made key contributions to the identification of replication functions, latent reservoir in myelomonocytic progenitors, immunomodulatory functions, and cellular response to viral infection. His research has opened dramatic new understanding of cell death pathways in host defense and development. He is the author and coauthor of more than 180 peer-reviewed articles. He received an A.B. from Rutgers University and a Ph.D. from the University of Iowa, both in Microbiology.